WHAT THIS PAPER ADDS A major proportion of large chronic tissue defects in the foot treated with free flap transfer are of diabetic origin with either neuro-ischaemic or predominantly neuropathic aetiology. Revascularisation in conjunction with free flap transfer may be necessary. This paper describes for the first time, the strategies for free flap transfer in both neuro-ischaemic and predominantly neuropathic large diabetic foot defects, as well as the long-term outcome in different treatment groups.
INTRODUCTION
The influence of chronic ischaemia on outcome after free flap transfer (FFT) in large diabetic foot lesions is a largely un-investigated issue. 1 In general, neuro-ischaemic diabetic foot lesions fare much worse than the purely neuropathic ones. 2, 3 In the absence of peripheral arterial disease (PAD), the free flap may be anastomosed to local vessels; however, when the local arterial circulation is insufficient, a preliminary vascular bypass for inflow is necessary. Previous series have mostly involved patients with combined FFT and vascular bypass in mixed series with diabetic and nondiabetic patients. Series including only patients with diabetes are available but a comparison of outcomes in patients with and without vascular reconstruction has not been performed. 1, 4 Therefore, this study analysed the long-term outcome of FFT in patients with diabetes with large chronic foot defects in three patient groups. Group A had predominantly neuropathic lesions with an in line native artery to the ulcer DOI of original article: http://dx.doi.org/10.1016/j.ejvs.2015.04.029area; group B had lesions with critical ischaemia treated with vascular bypass; and group C had lesions with uncorrectable critical ischaemia.
MATERIALS AND METHODS
Between 1991 and 2003, large tissue defects of the foot were debrided and covered with FFT in 63 patients with diabetes. According to the University of Texas wound classification system, 57 were 3AeD and six were 2AeD lesions. 5 The ulcer diameter exceeded 10 cm in 44% of the patients, whereas the smallest area was 5 Â 3 cm. In most patients, the ulcer extended to two or more angiosome regions. 6 The patients had undergone multiple revisions and many unsuccessful attempts at covering the tissue defect with skin grafting or local flaps in the past. Without proper wound excision and FFT, all patients would have faced major amputation.
Free flap surgery was considered if the tarsal bones and the body of the calcaneus could be saved, taking into account the general condition of the patient. The ability to walk or move a wheelchair independently had to be retained, and life expectancy had to be reasonable. The decision tree used is available in a previously published article. 7 A multidisciplinary team, consisting of a plastic and a vascular surgeon, specialists in internal medicine and in infectious diseases, and an anaesthesiologist, evaluated each candidate for FFT. An infection unresponsive to antibiotics and debridement, as well as a progressive gangrene of the foot despite revisions after proper revascularisation, were beyond the reach of even this kind of treatment.
A stressful peri-operative period and recovery time necessitated careful pre-operative evaluation of the general condition and cooperation of the patient. Uraemia was mostly considered as a contraindication. Two uraemic patients were operated on in 1995 and 1997. Suitability for general anaesthesia, prolonged operation time, and major bleeding were weighed carefully.
Procedure
The ulcers were first excised, along with all diseased bone, creating a fresh wound bed. The free flap was selected on the basis of the size, depth, and location of the defect. Furthermore, comorbidities related to flap raising and potential atherosclerosis in the flap vessels were evaluated. The 38 latissimus dorsi (LD), 11 rectus abdominis (RA), and eight forearm flaps (FA) were the most frequently used. LD and RA flaps were mainly covered with skin grafting, whereas FA flaps were fascio-cutaneous. The serratus muscle was used twice, and the gracilis, adductor, vastus lateralis, and parascapularis flaps once each, using a surgical technique described previously. 8 With vascular reconstruction, an in line arterial supply to the foot or ankle according to the ulcer location was created whenever possible. Of the 48 concomitant vascular reconstructions, 36 were performed simultaneously with the FFT. In staged operations, the FFT was performed if the ulcer showed no healing within 1e8 weeks, and in one case 1 year after the vascular reconstruction.
In vascular bypass operations, heparin was infused perioperatively before clamping the artery. In separate flap transfer operations with microvascular anastomosis only, no intravenous heparin was given. Post-operatively, low molecular weight heparin was administered in the surgical unit. Acetylsalicylic acid with daily dosage of 100 mg was introduced permanently except in patients on warfarin.
Design
The patients were divided retrospectively into three groups according to the presence and severity of PAD, based on the findings at angiography and at operation (Fig. 1) . This division was congruent with available non-invasive measurements ( Table 1 ). All patients, except five in group A, underwent a conventional pre-operative angiogram or digital subtraction angiogram. In these five patients the microvascular anastomosis was performed to a pedal vessel with a palpable pulse.
In group A (n ¼ 19), a patent native arterial line supplied the ulcer area. Patients were included in group A if the anterior tibial (ATA) or the posterior tibial artery (PTA) continued below malleolar level, supplying arterial circulation to the ulcer area in the foot, or if the ATA, PTA, or fibular artery reached the malleolar level and fed the ulcer area in the ankle and Achilles tendon region. These large lesions covered several angiosomes, and the angiosome concept as such could therefore not be used.
A local native artery served as the inflow vessel in 14 of 19 patients in group A. The remaining five patients had patent but calcified leg arteries, not suitable for microvascular anastomosis, and an end to end anastomosis was performed between an inflow conduit and the flap artery. The toe pressures in four of these five legs were 78, 64, 55 and 34 mmHg, respectively; in one patient, toe pressure measurements were not available. In the latter two patients, however, an arterial line was patent down to the foot on angiography. Three patients in group A underwent a preceding percutaneous transluminal angioplasty of a short stenosis in the superficial femoral artery or crural vessels. Their toe pressure values were between 56 and 69 mmHg before the angioplasties, which were performed to achieve the best possible circulation prior to major surgery.
Patients in group B (n ¼ 32) had correctable ischaemia. All patients underwent bypass of an occluded arterial line to an outflow vessel reaching the foot. The flap inflow was taken either end to side from the vascular graft (n ¼ 28) or from a native outflow artery (n ¼ 4).
Twenty-one patients had a simultaneous FFT and vascular reconstruction, whereas 11 had a staged operation. The simultaneous operation was done when the tissue defect already necessitated FFT pre-operatively. If the nearby tissues or skin grafting were not sufficient to cover the tissue defect, the staged operation was performed after a vascular reconstruction and subsequent revisions.
In group C (n ¼ 12), patients with uncorrectable ischaemia had an occluded arterial line without a distal outflow vessel. Reconstitution of direct flow to the ulcer area was thus not possible. A more proximal bypass was performed, if appropriate, with the flap inflow from the vascular graft (n ¼ 5). Otherwise, an end to end anastomosis between the flap artery and an inflow conduit from a more proximal native artery was performed (n ¼ 6). One patient with occluded pedal vessels had inflow from the distal ATA at the ankle.
Follow up and outcome measures
The follow up lasted until December 2009 or until patient death. Amputation free survival (AFS), leg salvage, survival, and ulcer healing time were assessed. The follow up data were retrieved from patient records of the Helsinki University Hospital, local hospitals, and healthcare centres, as well as home nursing records. Based on clinical experience of frequent recurrent ulceration, an ulcer was considered healed only if it remained epithelised for at least 6 months. However, the day when full epithelisation was observed for the first time was considered the date of healing.
The ethics committee of Helsinki University Central Hospital approved the study.
Statistics
Median and interquartile range were the descriptive statistics used. Categorical data were compared between the groups using the chi-square test or Fischer's test in case if any of the cells had an expected count of <5. The following risk factors for amputation in a dichotomous form were tested: sex, nephropathy (serum or plasma creatinine levels exceeding laboratory reference values, renal transplantation patients with increased creatinine, uraemia), type of diabetes, ever smoking, American Society for Anesthesiologists (ASA) score (4 vs. ASA 2 or 3), previous major amputation, type of flap (LD or RA vs. other flaps), ulcer properties (location in the heel and the forefoot vs. other locations, plantar involvement, greatest diameter >10 cm). Risk ratios with 95% confidence intervals (CIs) were calculated for significant risk factors in the chi-square test. The continuous variables that were tested using the ManneWhitney U test included body mass index, age, pre-operative C-reactive protein (CRP), toe pressure, and ankle brachial index (ABI). Survival was studied by means of KaplaneMeyer analysis. The estimated median survival was given with a 95% CI. Differences between groups were tested with the log rank test. A p-value < .05 was considered statistically significant. SPSS 17.0 (IBM, Armonk, NY, USA) was used for the statistical analyses.
RESULTS
At baseline, a significant difference between the groups was observed in respect of CRP, number of earlier major amputations, creatinine, lesion location, pre-operative toe pressure, and ABI (Table 1) .
Altogether, seven patients underwent ipsilateral endovascular treatment or vascular re-operation during the follow up, two in the patent native artery group, four in the 
correctable ischaemia group, and one in the uncorrectable ischaemia group.
Survival
The overall 30 day mortality was 3% (two patients). The survival rate at 1 year was 95% in group A, 94% in group B, and 92% in group C. The respective 5 year survival rates in groups A, B, and C were 84%, 47%, and 67%; the respective 10 year survival rates were 67%, 27%, and 21%. Estimated median survival in group A was 149 months (95% CI 90e 208), in group B 54 months (95% CI 17e91), and in group C 76 months (95% CI 52e100). Survival was significantly better in group A compared with groups B (p ¼ .001 and C (p ¼ .03)
Leg salvage and AFS
The overall 30 day amputation rate was 11% (seven patients). During follow up, a total of 19 (30%) legs underwent major amputation: two (11%) in group A, 11 (58%) in group B, and six (32%) in group C. The reasons for amputation were flap failure (n ¼ 7), persisting infection (n ¼ 4), a thrombosed vascular graft (n ¼ 4), persistent ulceration (n ¼ 2), and new ulceration (n ¼ 2). The estimated mean leg salvage time in group A (187 months; 95% CI 161e213) was significantly longer than in groups B (93 months; 95% CI 70e117) and 3 (75 months; CI 34e116) (Fig. 2) . After 1 year, only three major amputations were performed (at 14, 18, and 90 months, respectively). The final amputation level was above the knee in three patients; 10 patients ended up having bilateral below or above knee amputation.
The median AFS time was significantly longer in group A (149 months; 95% CI 92e206) compared with groups B (27 months; 95% CI 18e36) and C (11 months; 95% CI 0e53) (Fig. 3) .
Of the 41 patients retaining the leg with a flap at 12 months, 16 walked without restriction, 20 had restriction in distance or used a cane or walker, three were able to take some steps, and two were ambulating by wheelchair.
Risk factors for amputation
For the entire series, the risk of amputation was increased in smokers (relative risk [RR] 3.09, 95% CI 1.8e5.3; p ¼ .004) (Fig. 4) Figure 3 . Amputation free survival. The difference between groups A and each of B and C were significant (p < .001 and p ¼ .01) by KaplaneMeier log rank test.
patients at risk  51  38  37  31 28 25 25  21 20  17 15  10  6  3  12  6  3  3  3  3  3 months (95% CI 8e30); in group B, 56% (18/32) healed in 9 months (95% CI 6e13); and in group C, 33% (4/12) healed in 20 months (95% CI 6e35). The proportion of healed ulcers was greater in group A than in groups B (p ¼ .041) and 3 (p ¼ .007), whereas between groups B and C, the difference did not reach significance (p ¼ .061). There were no significant differences in healing times between the groups. Three legs (one in group A and two in group C) avoided amputation despite flap loss. Two healed after skin grafting in 5 and 13 months, respectively, and one after reamputation at proximal metatarsal level after 6 months. These patients were included in the KaplaneMeier analysis.
DISCUSSION
In a diabetic foot with a remarkable tissue defect, FFT may offer the last chance to avoid amputation. A selection of different strategies is necessary when treating these ulcers with FFT as the presence and pattern of atherosclerosis varies. A multidisciplinary decision to proceed to these major reconstructions was made after careful pre-operative evaluation. 7 It was found that the outcome of FFT in terms of leg salvage is highly associated with the severity of PAD and the possibility of revascularising the leg. The overall amputation rate in patients with a patent native artery was 10% versus the 30% in patients with correctable ischaemia and 50% in patients with uncorrectable lower leg ischaemia. Of note, by excluding smokers, the leg salvage rate in patients with a patent native artery corresponds roughly with the rate in patients with correctable ischaemia. Indeed, smoking and large ulcers, especially in the heel, as well as nephropathy are the most notable predictors of failure. However, the risk factor profile is a complex issue (other significant predictors of poor outcome cannot be stated) as half of the patients in the most unfortunate uncorrectable ischaemia group avoided major amputation.
Amputations mostly occurred in the first post-operative year, whereas mortality continued on a linear course in all groups during the follow up. The durability of leg salvage after 2 years was surprisingly good, considering the progressive nature of ischaemic disease. This may, in part, be attributable to the high early mortality of the most morbid patients. Recent severe foot problems probably also increased the watchfulness among the patients and their caregivers.
Patients with a patent artery, not needing a revascularisation, had a long survival and good probability of leg salvage. A remarkable number of patients with significant ischaemia had an AFS of many years. Surprisingly, revascularisation, mostly to the pedal vessels, did not seem to improve leg salvage significantly compared with patients with uncorrectable ischaemia. One explanation might be the more extensive tissue lesions in the correctable ischaemia group compared with the group with uncorrectable ischaemia.
It is likely that some patients with complicated defects but no recipient vessel were not considered to benefit from FFT and the procedure was never offered to them.
However, despite the anastomosis to a pedal vessel and the satisfactory post-operative toe pressure values, it is still possible that the most distal vessels were diseased. In all, the low number of patients in group C prevents definitive conclusions.
The similar mortality, significantly higher than in the native artery group, in the groups with correctable and uncorrectable ischaemia, reflects the increased risk of cardiovascular mortality in these patients with severe peripheral arterial disease. Remarkably however, despite the high mortality in patients with atherosclerosis, a benefit from such a major surgery can be achieved.
Ulcer size as a risk factor for limb loss is argued to make these procedures meaningless. This is a misconception, as only large and complicated lesions were considered for this kind of treatment. Indeed, not only the size but also the extent and location of the lesion may be problematic. The issue with size can be summarised in the question of whether the extensive lesions leaving very little of the foot untouched and extending over more than one angiosome could also have a capacity to heal with this kind of treatment.
Only two patients with uraemia, operated on in 1995 and 1997, were included in this cohort. Later, patients with uraemia were not treated with FFT, based on clinical experience and published reports. Paradoxically, both patients with uraemia retained their legs. However, in line with previous studies, high creatinine levels were associated with amputation. 4 Ulcer healing has rarely been reported in connection with FFT and diabetic or ischaemic ulcers. 7 Based, on the clinical experience of the authors, recurrent ulceration is frequent after FFT. Therefore, in this study, healing was defined as full epithelisation for a minimum of 6 months. In almost half of the patients, ulcers healed in 6 months, but in the other half, the healing took longer (up to 81 months).
Previously, FFT has mainly been studied in combination with vascular reconstruction in patients with or without diabetes. 4, 7, 9 In two large series, which combined FFT and revascularisation, the proportions of patients with diabetes were 71% and 76%, respectively. 4, 9 In those series, the 5 year limb salvage rates were 63% and 71%, respectively, similar to the data obtained in the present study; however, in this study, long-term mortality was higher, probably indicating a more morbid group of patients. Only a few cases of FFTs with an inflow from a proximal vessel directly to the flap in the absence of a recipient vessel in the foot, also called nutrient flaps, have been described previously. 4 ,10e12 Twelve such patients were included in the present study, six of whom reached at least 2 years of AFS. Patients with no need for vascular reconstruction have been included in earlier series of patients with diabetes, but their outcome has not been analysed separately. 4,13e15 Angiographic findings were the main methods used to distinguish the extent of occlusive arterial lesions in the present study. Pre-operative angiography is a valuable method for predicting outcome after femoro-crural bypass surgery. 16 For 16 patients ABI and toe pressure values were not available owing to foot level amputations, medial sclerosis, and challenging logistics related to many diagnostic procedures, urgent operations, and transfers from other hospitals. TcpO 2 measurement, which was reestablished successfully in recent years after a long pause due to reliability issues, might have been of assistance. Novel methods popularised over the last 15 years, such as crural and pedal PTA and negative pressure wound therapy, especially in the most severe cases, can serve as an adjuvant to FFT, ideally with an improved outcome for the patient. 17 
CONCLUSION
Even in diabetic patients with significant comorbidities and complicated large leg ulcers, excellent long-term AFS may be expected with free flap coverage in the presence of a patent native artery. Ischaemic limbs in patients with diabetes may also often be salvaged with a combination of a free flap and vascular reconstruction. Diseased run-off vessels not allowing proper revascularisation should lead to a meticulous weighing of the risks and benefits of the operation; however, half of these procedures were successful in the present series. Smoking and a large ischaemic ulcer in the heel are predictors for unfavorable outcome. In the most diseased patients, amputation should be considered in order to avoid unnecessary major surgery and rehabilitation.
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